EOLS vs LFCR
EOLS: A global performance beauty company specializing in injectable aesthetic products, primarily botulinum toxin (Jeuveau®) and hyaluronic acid gels (Evolysse™), for the direct-pay medical aesthetics market. LFCR: Lifecore Biomedical is a specialized CDMO focused on complex sterile injectable fill-finish and manufacturing services for the pharmaceutical industry.
Side-by-side fundamentals
| Metric | EOLS | LFCR | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $6.01 | $4.34 | |
| Market cap as of 2026-07-31 | $393M | $161M | |
| Net margin as of 2026-07-31 | -14.4% | -26.5% | EOLS higher |
| Gross margin as of 2026-07-31 | +66.1% | +30.0% | EOLS higher |
| Operating margin as of 2026-07-31 | -8.1% | -1.9% | LFCR higher |
| ROE as of 2026-07-31 | -410.2% | -126.8% | LFCR higher |
| ROA as of 2026-07-31 | -19.4% | -18.9% | LFCR higher |
| Debt / equity as of 2026-07-31 | 22.00 | 7.16 | LFCR lower |
| Revenue growth (YoY) as of 2026-07-31 | +9.6% | +27.6% | LFCR higher |
| Revenue CAGR (3y) SEC XBRL | +26.0% | +5.3% | EOLS higher |
| Beta as of 2026-07-31 | 1.22 | 1.15 | |
| 1-year return as of 2026-07-30 close | -32.9% | -41.6% | EOLS higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.